Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Wound healing modulation through OloGen after trabeculectomy

Poster Details

First Author: S. Fili GERMANY

Co Author(s):    M. Kohlhaas                    

Abstract Details


To report on the surgical results and the complications of trabeculectomy with OloGen in our ophthalmological department.


Setting: Dr. med. S. Fili, MD1, Prof. Dr. med. M. Kohlhaas,MD2. 1 Resident in the department of Ophthalmology, St-Johannes-Hospital, Dortmund 2 Director of the department of Ophthalmology, St-Johannes-Hospital, Dortmund


In our institution we use OloGen implants of 7 mm in diameter and 4 mm thick. Since 2007 we have performed over 3000 trabeculectomies using OloGen with Mitomycin-C. Since middle of 2009 is this combination standard procedure in our department.


Trabeculectomy is the mainstay of surgical treatment for long-term management of IOP and carries a high risk of scarring due to fibroblast proliferation in the subconjunctival space, which blocks the outflow of aqueous humour, and leads therefore to high failure rates. The control of scarring can be modified by using intraoperatively Mitomycin C or by the application of steroids with 5-Fluoracil postoperatively. Since 2006 an OloGen-Implant is in Germany available to be inserted under the conjunctiva. The matrix of this implant completely degrades within 90–180 days and leaves behind a loose alignment of collagen fibers that is remarkably similar to normal tissue with less scar formation than would otherwise have occurred and better function of the bleb.


Our data demonstrate a satisfied control of scarring after trabeculectomy with OloGen as well as a significant important maintenance of the function of bleb in this group in comparison to the group that underwent a trabeculectomy without OloGen.

Financial Disclosure:


Back to Poster listing